Vivanza Biosciences Limited (BOM:530057)
1.940
+0.130 (7.18%)
At close: Jul 28, 2026
Vivanza Biosciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 78 | 70 | 80 | 272 | 752 | 755 | |
Market Cap Growth | -9.35% | -11.56% | -70.69% | -63.88% | -0.34% | 44.45% |
Enterprise Value | 179 | 166 | 140 | 322 | 807 | 784 |
Last Close Price | 1.94 | 1.76 | 1.99 | 6.79 | 18.80 | 18.86 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 19.40 | 17.85 | - | 49.63 | 125.69 | 226.61 |
PS Ratio | 0.07 | 0.06 | 1.07 | 0.97 | 4.14 | 6.74 |
PB Ratio | 1.78 | 1.62 | 2.01 | 5.86 | 18.38 | 21.61 |
P/TBV Ratio | 2.85 | 2.59 | 3.42 | 9.05 | 30.62 | 40.63 |
P/FCF Ratio | - | - | - | 13.54 | - | 30.59 |
P/OCF Ratio | - | - | - | 13.29 | - | 30.59 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.15 | 0.14 | 1.88 | 1.16 | 4.44 | 7.00 |
EV/EBITDA Ratio | 21.18 | 19.62 | - | 28.78 | 70.90 | 91.48 |
EV/EBIT Ratio | 21.74 | 20.14 | - | 29.10 | 71.06 | 92.28 |
EV/FCF Ratio | - | - | - | 16.07 | - | 31.78 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 2.34 | 2.34 | 2.18 | 1.12 | 1.96 | 1.58 |
Debt / EBITDA Ratio | 12.07 | 12.07 | - | 4.61 | 7.03 | 6.43 |
Debt / FCF Ratio | - | - | - | 2.58 | - | 2.23 |
Net Debt / Equity Ratio | 2.32 | 2.32 | 2.15 | 1.07 | 1.91 | 1.56 |
Net Debt / EBITDA Ratio | 11.99 | 11.99 | -29.22 | 4.44 | 6.88 | 6.36 |
Net Debt / FCF Ratio | -3.75 | -3.75 | -3.39 | 2.48 | -8.28 | 2.21 |
Asset Turnover | 6.02 | 6.02 | 0.42 | 1.33 | 0.96 | 0.93 |
Inventory Turnover | 39.36 | 39.36 | 3.20 | 11.58 | 6.73 | 6.26 |
Quick Ratio | 0.74 | 0.74 | 0.90 | 0.96 | 0.75 | 0.83 |
Current Ratio | 1.13 | 1.13 | 1.35 | 1.29 | 1.15 | 1.31 |
Return on Equity (ROE) | 9.48% | 9.48% | -15.67% | 12.54% | 15.78% | 10.01% |
Return on Assets (ROA) | 2.67% | 2.67% | -1.06% | 3.30% | 3.73% | 4.42% |
Return on Invested Capital (ROIC) | 4.17% | 4.43% | -2.76% | 8.11% | 9.09% | 10.91% |
Return on Capital Employed (ROCE) | 15.70% | 15.70% | -4.20% | 15.10% | 20.50% | 14.00% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 5.08% | 5.60% | -8.47% | 2.02% | 0.80% | 0.44% |
FCF Yield | -34.84% | -38.40% | -31.49% | 7.39% | -1.26% | 3.27% |
Buyback Yield / Dilution | 1.40% | 1.40% | -2.32% | 2.27% | - | - |